Therapeutic targeting of metabolic alterations in acute respiratory distress syndrome. (3rd July 2020)

• Record Type: Journal Article
• Authors: Robinson, Matthew John; Krasnodembskaya, Anna D.
• Is Part Of: European respiratory review. Volume 29:Number 156(2020)
• Publication Date: 2020-07-03
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiratory Tract Diseases; Respiratory organs -- Diseases; Respiratory organs -- Diseases -- Treatment; Electronic journals; Periodical; Periodicals; Periodicals; 616.2
• DOI: 10.1183/16000617.0114-2020
• Languages: English
• ISSNs: 0905-9180

Abstract

Acute respiratory distress syndrome (ARDS) remains a significant source of mortality in critically ill patients. Characterised by acute, widespread alveolar inflammation and pulmonary oedema, its pathophysiological heterogeneity has meant that targeted treatments have remained elusive. Metabolomic analysis has made initial steps in characterising the underlying metabolic derangements of ARDS as an indicator of phenotypical class and has identified mitochondrial dysfunction as a potential therapeutic target. Mesenchymal stem cells and their derived extracellular vesicles have shown significant promise as potential therapies in delivering mitochondria in order to redivert metabolism onto physiological pathways. ARDS' biological heterogeneity is an obstacle in clinical translation of interventions. Analysis of metabolic alterations can inform development of therapeutics aimed at ARDS subpopulations. Mitochondrial dysfunction may be a potential therapeutic target .https://bit.ly/2XHfAFV